Influence of cytotoxic T lymphocyte-associated antigen 4 (CTLA4) common polymorphisms on outcome in treatment of melanoma patients with CTLA-4 blockade - PubMed (original) (raw)

Influence of cytotoxic T lymphocyte-associated antigen 4 (CTLA4) common polymorphisms on outcome in treatment of melanoma patients with CTLA-4 blockade

Willemijn B Breunis et al. J Immunother. 2008 Jul-Aug.

Abstract

Blockade of the cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), a down-regulator of T-cell activation, can cause cancer regression in patients with metastatic melanoma. However, not all patients respond well to the therapy and some develop severe autoimmune reactions. We hypothesized that common genetic variation in the CTLA4 gene could contribute to response to CTLA-4 blockade and the occurrence of autoimmune reactions. We investigated 7 common single nucleotide polymorphisms, SNPs, (rs733618, rs4553808, rs11571317, rs5742909, rs231775, rs3087243, and rs7565213) in 152 white melanoma patients who received CTLA-4 blockade. Three SNPs were associated with response to therapy: proximal promoter SNPs, rs4553808 [P=0.002; odds ratio (OR) 3.39; 95% confidence interval (CI), 1.62-7.10] and rs11571327 (P=0.02; OR 2.89; 95% CI, 1.23-6.83) and the nonsynonymous SNP rs231775 (Thr17Ala, P=0.009; OR 0.39; 95% CI, 0.18-0.82). A haplotype analysis including the 7 SNPs suggested that the common haplotype, TACCGGG could be associated with no response (P=0.02) whereas the haplotype TGCCAGG (P=0.06; OR 4.13; 95% CI, 1.17-14.5) could be associated with response to the treatment. No significant association was observed for occurrence of severe autoimmune reactions (grade III/IV) either by single SNP or haplotype analyses. Our results suggest that genetic variation in CTLA4 could influence response to CTLA-4 blockade therapy in metastatic melanoma patients, but further studies are necessary to confirm the observed associations.

PubMed Disclaimer

Cited by

Germline immunomodulatory expression quantitative trait loci (ieQTLs) associated with immune-related toxicity from checkpoint inhibition.
Ferguson R, Chat V, Morales L, Simpson D, Monson KR, Cohen E, Zusin S, Madonna G, Capone M, Simeone E, Pavlick A, Luke JJ, Gajewski TF, Osman I, Ascierto P, Weber J, Kirchhoff T. Ferguson R, et al. Eur J Cancer. 2023 Aug;189:112923. doi: 10.1016/j.ejca.2023.05.011. Epub 2023 May 18. Eur J Cancer. 2023. PMID: 37301715 Free PMC article.
Pharmacogenomics for Prediction of Cardiovascular Toxicity: Landscape of Emerging Data in Breast Cancer Therapies.
Altena R, Bajalica-Lagercrantz S, Papakonstantinou A. Altena R, et al. Cancers (Basel). 2022 Sep 25;14(19):4665. doi: 10.3390/cancers14194665. Cancers (Basel). 2022. PMID: 36230587 Free PMC article. Review.
Insights Into the Host Contribution of Endocrine Associated Immune-Related Adverse Events to Immune Checkpoint Inhibition Therapy.
Chye A, Allen I, Barnet M, Burnett DL. Chye A, et al. Front Oncol. 2022 Jul 14;12:894015. doi: 10.3389/fonc.2022.894015. eCollection 2022. Front Oncol. 2022. PMID: 35912205 Free PMC article. Review.
Germline genetic host factors as predictive biomarkers in immuno-oncology.
Chat V, Ferguson R, Kirchhoff T. Chat V, et al. Immunooncol Technol. 2019 Sep 5;2:14-21. doi: 10.1016/j.iotech.2019.08.001. eCollection 2019 Sep. Immunooncol Technol. 2019. PMID: 35756849 Free PMC article. Review.
Pharmacogenetics of anticancer monoclonal antibodies.
Shek D, Read SA, Ahlenstiel G, Piatkov I. Shek D, et al. Cancer Drug Resist. 2019 Mar 19;2(1):69-81. doi: 10.20517/cdr.2018.20. eCollection 2019. Cancer Drug Resist. 2019. PMID: 35582142 Free PMC article. Review.

References

1. Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA. 2003;100:8372–77. - PMC - PubMed
1. Hodi FS, Mihm MC, Soiffer RJ, et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA. 2003;100:4712–17. - PMC - PubMed
1. Attia P, Phan GQ, Maker AV, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol. 2005;23:6043–53. - PMC - PubMed
1. Abrams SI. Role of anti-CTLA-4 therapies in the treatment of cancer. Curr Opin Mol Ther. 2004;6:71–77. - PubMed
1. Gough SC, Walker LS, Sansom DM. CTLA4 gene polymorphism and autoimmunity. Immunol Rev. 2005;204:102–15. - PubMed

Influence of cytotoxic T lymphocyte-associated antigen 4 (CTLA4) common polymorphisms on outcome in treatment of melanoma patients with CTLA-4 blockade - PubMed (original) (raw)